Tratamento da síndrome antifosfolípides na gestação

Barros, Venina Viana de

doi:10.1590/s0104-42302002000200022

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its main mechanism of action is the irreversible inhibition of cyclooxygenase isoenzyme activity in platelets. Thus, it blocks prostaglandin (PGI2) synthesis in endothelial cells, promoting inhibition of platelet aggregation and adhesion, allowing vasodilator effect [28,29]. In this study the frequency of these thrompohilias did not allow any conclusions to be drawn about this treatment association.…”

Section: Resultsmentioning

confidence: 81%

Heparin Use in Pregnant Women Diagnosed With Thrombophilia: Obstetric Outcomes

Andrade¹,

Camargos²,

Reis³

et al. 2019

Clinics Mother Child Health

View full text Add to dashboard Cite

Introduction: Thrombophilias are associated with venous thromboembolism. According to reports, uteroplacental thrombosis can lead to preeclampsia, intrauterine growth restriction (IUGR), placental abruption (PA) and even to fetal death. The Brazilian Ministry of Health recommends the application of heparin treatment-associated, or not, with ASA to pregnant women diagnosed with thrombophilia, based on its type. However, many studies have not been able to confirm the beneficial effects of heparin use on maternal and fetal health. Methods: The current research is a case-control study comprising pregnant women treated at the Obstetrics Service of Federal University of Juiz de Fora and at the Medical School of Barbacena, who used heparin in the current pregnancy due to previously diagnosed thrombophilia. Current pregnancy associated with heparin use was named 'case', whereas previous pregnancy without heparin use was named 'control'. Thus, 47 cases (current pregnancy) and 32 controls were selected (1,4 cases: 1,0 control). Results: Association between heparin and miscarriage, intrauterine fetal death and preeclampsia were analyzed. Results showed that heparin acted as protective factor against miscarriage (OR=0.04; CI=0.01-0.14; p<0.0001), intrauterine fetal death (OR=0.01; CI=0.01-0.11; but heparin use did not reduce the frequency of preeclampsia cases (OR=0.35; CI=0.07-1.6; p=0.17). Conclusion: Based on the current results, the early heparin application to pregnant women with thrombophilia was able to reduce the number of miscarriage, intrauterine death, but did not reduce the frequency of preeclampsia.

show abstract

Section: Resultsmentioning

confidence: 81%